Literature DB >> 29796984

Subsequent infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in patients with prior infection or fecal colonization.

Anna Lindblom1,2, Nahid Karami3,4, Tim Magnusson4, Christina Åhrén3,5.   

Abstract

In clinical practice, there is a growing need to assess the impact of prior colonization or infection with extended-spectrum β-lactamase-producing Enterobacteriaceae (EPE) on new EPE infections. We have investigated the frequency of, and duration to, a subsequent EPE infection in patients with prior fecal carriage or infection with EPE. Culture data for 3272 EPE-positive patients in Western Sweden during 2004-2014 were evaluated. The median follow-up time was 3.7 years. The first recorded EPE-positive fecal screen, or clinical (urine, blood) culture, and subsequent EPE-positive clinical samples were analyzed, focusing on the first and last recurrence of EPE infection. ESBL Escherichia coli dominated (95%). Almost all (94%) patients initially positive in fecal screen (n = 1436) and 72 and 71% of those initially positive in urine (n = 1717) and blood (n = 119) had no further EPE clinical isolates. Subsequent EPE bacteremia was only detected in 0.7, 1.6, and 4.2% of the respective patient group. Recurrent EPE-positive urine cultures occurred in 27% (460/1717), most (75%) within 6 months, and rarely (13%) after 1 year. Repeated EPE-positive clinical samples were significantly (p < 0.01) more common in patients > 65 years and in men with ESBL Klebsiella pneumoniae. In our low-endemic setting, subsequent EPE infections in previously colonized patients were rare. On the other hand, in patients previously EPE-positive in urine or blood, subsequent EPE urinary tract infections were common, especially within 6 months and in patients > 65 years old.

Entities:  

Keywords:  Bacteremia; E. coli; Extended-spectrum β-lactamases (ESBL); Fecal screening; K. pneumoniae; Recurrent infection; Urinary tract infection

Mesh:

Substances:

Year:  2018        PMID: 29796984     DOI: 10.1007/s10096-018-3275-x

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  26 in total

1.  Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.

Authors:  Mitchell J Schwaber; Yehuda Carmeli
Journal:  J Antimicrob Chemother       Date:  2007-09-11       Impact factor: 5.790

2.  Editorial Commentary: Fecal ESBL Screening: Are We Ready for This Information?

Authors:  Sarah E Turbett; Michael K Mansour
Journal:  Clin Infect Dis       Date:  2016-05-03       Impact factor: 9.079

Review 3.  Colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae and risk for infection among patients with solid or haematological malignancy: a systematic review and meta-analysis.

Authors:  Michail Alevizakos; Styliani Karanika; Marios Detsis; Eleftherios Mylonakis
Journal:  Int J Antimicrob Agents       Date:  2016-10-06       Impact factor: 5.283

4.  Risk factors for second urinary tract infection among college women.

Authors:  B Foxman; B Gillespie; J Koopman; L Zhang; K Palin; P Tallman; J V Marsh; S Spear; J D Sobel; M J Marty; C F Marrs
Journal:  Am J Epidemiol       Date:  2000-06-15       Impact factor: 4.897

5.  Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia.

Authors:  José A Martínez; Josefa Aguilar; Manel Almela; Francesc Marco; Alex Soriano; Fina López; Valentina Balasso; Laura Pozo; Josep Mensa
Journal:  J Antimicrob Chemother       Date:  2006-09-01       Impact factor: 5.790

Review 6.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

7.  Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women.

Authors:  R Ikäheimo; A Siitonen; T Heiskanen; U Kärkkäinen; P Kuosmanen; P Lipponen; P H Mäkelä
Journal:  Clin Infect Dis       Date:  1996-01       Impact factor: 9.079

8.  Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients.

Authors:  Laurence Armand-Lefèvre; Cécile Angebault; François Barbier; Emilie Hamelet; Gilles Defrance; Etienne Ruppé; Régis Bronchard; Raphaël Lepeule; Jean-Christophe Lucet; Assiya El Mniai; Michel Wolff; Philippe Montravers; Patrick Plésiat; Antoine Andremont
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

9.  Recurring urinary tract infection: incidence and risk factors.

Authors:  B Foxman
Journal:  Am J Public Health       Date:  1990-03       Impact factor: 9.308

10.  Risk factors for developing ESBL E. coli: can clinicians predict infection in patients with prior colonization?

Authors:  T Goulenok; A Ferroni; E Bille; H Lécuyer; O Join-Lambert; P Descamps; X Nassif; J-R Zahar
Journal:  J Hosp Infect       Date:  2013-07-08       Impact factor: 3.926

View more
  7 in total

1.  The impact of the ST131 clone on recurrent ESBL-producing E. coli urinary tract infection: a prospective comparative study.

Authors:  Anna Lindblom; Camilla Kiszakiewicz; Erik Kristiansson; Shora Yazdanshenas; Nina Kamenska; Nahid Karami; Christina Åhrén
Journal:  Sci Rep       Date:  2022-06-16       Impact factor: 4.996

2.  Antibiotic-resistant organisms establish reservoirs in new hospital built environments and are related to patient blood infection isolates.

Authors:  Kimberley V Sukhum; Erin P Newcomer; Candice Cass; Meghan A Wallace; Caitlin Johnson; Jeremy Fine; Steven Sax; Margaret H Barlet; Carey-Ann D Burnham; Gautam Dantas; Jennie H Kwon
Journal:  Commun Med (Lond)       Date:  2022-06-01

3.  Risk factors associated with prolonged intestinal colonization of ESBL-producing Enterobacteriaceae - a prospective cohort study.

Authors:  Oskar Ljungquist; Marcus Schönbeck; Kristian Riesbeck; Johan Tham
Journal:  Infect Drug Resist       Date:  2019-08-26       Impact factor: 4.003

4.  Extended spectrum beta-lactamase producing Enterobacterales faecal carriage in a medical intensive care unit: low rates of cross-transmission and infection.

Authors:  Renaud Prevel; Alexandre Boyer; Fatima M'Zali; Thibaut Cockenpot; Agnes Lasheras; Véronique Dubois; Didier Gruson
Journal:  Antimicrob Resist Infect Control       Date:  2019-07-10       Impact factor: 4.887

5.  Prior Carriage Predicts Intensive Care Unit Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.

Authors:  Hatem Kallel; Stephanie Houcke; Dabor Resiere; Thibault Court; Cesar Roncin; Mathieu Raad; Flaubert Nkontcho; Magalie Demar; Jean Pujo; Didier Hommel; Felix Djossou
Journal:  Am J Trop Med Hyg       Date:  2022-01-10       Impact factor: 2.345

6.  Identity of blaCTX-M Carrying Plasmids in Sequential ESBL-E. coli Isolates from Patients with Recurrent Urinary Tract Infections.

Authors:  Nahid Karami; Sriram Kk; Shora Yazdanshenas; Yii-Lih Lin; Daniel Jaén-Luchoro; Elina Ekedahl; Sanjana Parameshwaran; Anna Lindblom; Christina Åhrén; Fredrik Westerlund
Journal:  Microorganisms       Date:  2021-05-25

7.  Fecal Carriage Rate of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae as a Proxy Composite Indicator of Antimicrobial Resistance in a Community in Thailand.

Authors:  Visanu Thamlikitkul; Teerawit Tangkoskul; Chakkraphong Seenama
Journal:  Open Forum Infect Dis       Date:  2019-09-30       Impact factor: 3.835

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.